Missing the primary endpoint in a phase 3 trial will not stop Pfizer from submitting Valneva-partnered Lyme disease vaccine for approval.

Apogee Therapeutics said its moderate-to-severe eczema candidate could offer much more convenient dosing over standard treatments based on its latest mid-stage results. Monday’s Phase 2

Insmed’s Phase 3 trial win for Arikayce in a particular kind of lung infection sets up the drug to expand into the front-line setting —

Sanofi is back in the T cell engager business after a couple years of fluctuating interest, extending its support to a relatively unknown California startup

Pfizer’s final-stage trial of its long-awaited Lyme disease vaccine missed its primary endpoint, but the drugmaker said it still plans to try to take the